DEF 14A: SeaStar Medical Holdings Corporation Announces 2024 Annual Meeting of Stockholders

SeaStar Medical Holding Corporation will hold its 2024 Annual Meeting of Stockholders virtually on June 4, 2024, to vote on director elections, an equity incentive plan amendment, a Nasdaq proposal, and auditor ratification.

Summary

• SeaStar Medical Holding Corporation will hold its Annual Meeting of Stockholders on June 4, 2024, virtually.
• Stockholders will vote on the election of three Class II Directors, the approval of an amendment and restatement of the 2022 Omnibus Equity Incentive Plan to increase the authorized shares from 3,278,457 to 9,778,457, and the approval of the Nasdaq Proposal regarding the issuance of shares upon exercise of warrants.
• Additionally, stockholders will vote to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote is April 26, 2024.
• As of the record date, there were 75,419,458 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: The document is primarily procedural, outlining the agenda for the annual meeting. While there are some positive aspects, such as the intention to attract and retain talent, there are also negative aspects, such as the potential dilution of existing stockholders' equity. The sentiment is neutral overall.

Positives

• The proposed amendment to the 2022 Omnibus Equity Incentive Plan aims to attract, retain, and motivate employees, directors, and consultants.
• The Board believes that the Plan is in the best interests of the business and stockholders.
• The engagement of Saratoga Proxy Consulting LLC should improve the efficiency of the proxy solicitation process.
• The company has adopted a compensation clawback policy in compliance with the Dodd-Frank Act.

Negatives

• The potential issuance of shares upon warrant exercises could dilute existing stockholders' equity.
• The company has had to restate financial statements for 2022 and the first three quarters of 2023.
• A portion of the base salary for 2023 was paid in shares of common stock in-lieu of cash due to financial constraints.

Risks

• Failure to obtain stockholder approval for the Nasdaq Proposal could limit the company's ability to issue shares and raise capital.
• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or a change in control of the Company.
• The company's ability to successfully develop its product candidate and implement its business plans and ultimately generate value for its stockholders is dependent upon its ability to raise capital to fund the regulatory approval process and to commercialize its products.

Future Outlook

The company is seeking stockholder approval to continue its operations and access required capital to fund its development efforts.

Management Comments

• Eric Schlorff, Director and Chief Executive Officer, urges stockholders to promptly vote and thanks them for their support.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy solicitations, director elections, and executive compensation disclosures. The need to increase the equity incentive plan share reserve suggests the company is actively using equity to attract and retain talent, which is common in the biopharmaceutical industry.

Comparison to Industry Standards

• The structure of the board with staggered terms is a common but controversial practice, as it can hinder potential takeovers but also provide stability.
• The executive compensation disclosures follow SEC guidelines for smaller reporting companies, which are less extensive than those required for larger companies.
• The engagement of a proxy solicitation firm is standard practice to ensure sufficient stockholder participation in the annual meeting.
• The company's clawback policy aligns with Dodd-Frank Act requirements, which are now standard for publicly listed companies.

Management Changes

Corporate Governance

Related Party Transactions

• On April 12, 2022, SeaStar Medical entered into a Convertible Bridge Loan Note Purchase Agreement with the Dow Pension Funds for the issuance and sale of convertible promissory notes with a total principal amount of $800,000 at an interest rate of 8% per year.
• On April 12, 2022, SeaStar Medical entered into a Convertible Note Purchase Agreement with certain holders (not including the Dow Pension Funds) of Series A-2 Preferred Stock and Series B Preferred Stock of the Company, pursuant to which SeaStar Medical issued a total of approximately $422,000 in principal amount of convertible notes.
• On August 23, 2022, LMAO entered into Subscription Agreements with the PIPE Investors pursuant to which the PIPE Investors have agreed to purchase, and LMAO has agreed to sell, an aggregate of 700,000 shares of Common Stock at $10.00 per share and the PIPE Warrants for an aggregate purchase price of $7,000,000.
• On April 21, 2022 and in connection with the execution of the Merger Agreement, certain stockholders of SeaStar Medical and LMAO entered into the Amended and Restated Registration Rights Agreement, pursuant to which the Company is required to file, not later than 30 days after the closing date of the Business Combination, a registration statement covering the shares of Common Stock issued or issuable to the Registration Rights Stockholders.
• On the closing date of the Business Combination, the Sponsor and LMAO entered into the Director Nomination Agreement, providing the Sponsor with certain director nomination rights, including the right to appoint or nominate for election to the Board, as applicable, two individuals, to serve as Class II directors of the Company, for a certain period following the Closing.
• On October 28, 2022, SeaStar Medical and LMFA entered into the First Amendment to Credit Agreement, pursuant to which the parties amended the Credit Agreement and entered into the LMFA Note to (i) extend the maturity date of the loan under the Credit Agreement to October 30, 2023; (ii) permit the LMFA Note be prepaid without premium or penalty; (iii) require the Company to use 5.0% of the gross cash proceeds received from any future debt and equity financing to pay outstanding balance of LMFA Note, provided that such repayment is not required for the first $500,000 of cash proceeds; (iv) reduce the interest rate of the LMFA Note from 15% to 7% per annum; and (iv) reduce the default interest rate from 18% to 15%.
• On October 28, 2022, the Company entered into the Sponsor Note with Sponsor as the lender, for an aggregate principal amount of $2,785,000 to amend and restate in their entirety the Original Notes.

Stakeholder Impact

• Shareholders will be impacted by the decisions made at the Annual Meeting, including the election of directors and the approval of the equity incentive plan amendment.
• Employees may be impacted by the equity incentive plan amendment, which could affect their compensation and incentives.
• The company's ability to raise capital and fund its operations will impact its ability to serve its customers and partners.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on June 4, 2024.
• The company will file a registration statement to register the resale of the Common Warrant Shares no later than 30 calendar days of the Stockholder Approval Date.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Equity Incentive Plan, Director Election, Nasdaq Proposal, Warrants, Auditor Ratification, Corporate Governance, Executive Compensation, SeaStar Medical